The global impact of Precision Medicine Group.
As it happens.
Impact, observations, and insights on the evolving healthcare landscape.
Gene therapy continues to evolve rapidly – from the science to the regulatory requirements. To give you a greater perspective on recent developments, this panel discussion brings together gene therapy experts across assay development, regulatory submissions, and clinical trial strategy who will share observations from the front lines on a multitude of gene therapy and rare disease projects.
Precision will be at this year’s Meeting on the Mesa conference from October 11 – 13, 2022, in Carlsbad, CA. Connect with our team of experts as they lead meaningful discussions and host events providing insights into the clinical development, manufacturing, and commercialization for advanced therapies.
There is a big need for therapeutic advancement in the rare disease community – however, public markets are stifling innovation and development for advanced medicines. This webinar, on Thursday, September 15th, will examine the current markets, their effect on the innovation in rare disease drug development, and what we can do to help.
Precision will be at this year’s CAR-TCR summit on September 19-22, 2022, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for CAR and TCR therapies.
As a wave of up-and-coming cell and gene therapies eye the path to approval soon, a combination of uncertainties threatens the waters ahead. A lack of talent, shortage of manufacturing, standardization, and shifting infrastructure are just the beginning of a range of potential issues.
Join Endpoints News and Precision ADVANCE for Cell & Gene Day, a free virtual event on August 24, from 12:00-4:00 PM ET where we convene three distinguished panels of experts to find out where the field stands today and explore funding, development and launch strategies to smooth out the ride to commercialization. You will hear from successful innovators from each facet of the CGTx landscape, including executives from Blackstone, Flagship Pioneering, Monograph Capital, Alliance for Regenerative Medicine, Satellite Bio, Cellevolve Bio, and more.
As payers began to deal with increased costs in 2021 due to deferred care during the COVID-19 pandemic, they still continued to grapple with the prospect of the impact of future gene therapies’ cost, according to industry experts. Precision’s Phil Cyr (SVP) and Erin Lopata (VP, Access Experience Team) weigh in on new ways to pay for the potential flood of gene therapies for rare diseases brewing in the pipeline.
This panel discussion, at ARM’s 2022 Meeting on the Med conference, focused on the sector’s continued success and challenges that lie ahead in research and development, manufacturing, regulatory, pricing, and reimbursement. Watch our panel of industry experts discuss the future of advanced medicines with emerging technologies like gene editing, non-viral delivery methods, and allogeneic cell therapies.
If a genetic therapy was created to cure sickle cell disease, how might this affect the productivity and earnings of an individual with the disease? How might this change also affect wider economic disparities? PRECISIONheor’s Marlon Graf (Senior Research Economist), Rifat Tuly (Research Scientist), and Jeff Sullivan (Senior Director) recently constructed a model to answer these impactful questions.
Precision will be at this year’s BIO International Convention from June 13 – 16 in San Diego, California. Connect with our team of experts throughout the event by joining our expert session, meeting our team at the booth, or attending our private Cell & Gene reception co-hosted by Precision ADVANCE and the Alliance for Regenerative Medicine (ARM).
The advanced therapies sector is growing exponentially. The Alliance for Regenerative Medicine (ARM) reports that the sector raised $23.1 billion in 2021 – a 16% year-over-year increase. That figure includes $1.9 billion in private financing and $9.8 billion in venture funding.